A Phase 2a Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic (PD) Study of Intravenous ANX005 in Subjects With Amyotrophic Lateral Sclerosis (ALS)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 08 Jan 2025

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs ANX 005 (Primary)
Indications Amyotrophic lateral sclerosis
Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Proof of concept
Sponsors Annexon

26 Mar 2024 According to an Annexon media release, company plans to submit the Phase 2a data for presentation at an upcoming medical conference later this year.
26 Mar 2024 Topline results from this trial presented in an Annexon media release.
26 Mar 2024 Status changed from recruiting to completed, according to an Annexon media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com